Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04571892
Other study ID # ScTIL210-003-2020
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 15, 2020
Est. completion date December 2024

Study information

Verified date April 2023
Source Shanghai East Hospital
Contact Jin Li, MD,PhD
Phone +86
Email lijin@csco.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, single-arm, single-dose escalation and multiple-dose expansion clinical study of cell therapy to observe and to evaluate the tolerance, the pharmacokinetic characteristics, the safety, and the efficacy of ScTIL210 in the treatment of malignant


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date December 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - When patients meet ALL of the following requirements, they will be eligible to be recruited, at their own wills, to participate in the clinical study. 1. Age = 18 years old and = 75 years old, regardless of gender; 2. An expected survival duration of longer than 3 months; 3. Patients with malignant solid tumor as confirmed by histology or cytology who failed in their prior standard therapies , or there is no recommended standard treatment, or a standard treatment is not applicable at this time; 4. The proportion of PD-1 positive T lymphocytes to the total T lymphocytes is = 18%. For patients who received PD-1 monoclonal antibody treatment within 4 weeks before screening, the proportion of PD-1 positive T to the total T lymphocytes is = 12%; 5. In accordance to RECIST version 1.1, there is at least one evaluable tumor focus for dose escalation phase; or there is at least one measurable tumor focus for dose expansion stage; 6. ECOG physical status score of between 0 to 1; 7. Sufficient bone marrow and organ function; Blood system:no transfusion or hematopoietic stimulating factor treatment within 14 days; Neutrophil count (ANC): = 1.5 × 109/L; Platelet (PLT): = 75 × 109/L; Hemoglobin (HB): = 90 g/L; Absolute lymphocyte count (lym): =60% of the lower limit of normal range; Lymphocyte subsets:Percentage of B lymphocyte (CD19+) to the total lymphocyte of =9%; Liver function Total bilirubin (TBIL) : = 1.5 × ULN Alanine aminotransferase (ALT): = 3 × ULN; for patients with liver metastasis or liver cancer: = 5 × ULN Aspartate aminotransferase (AST): = 3 × ULN; for patients with liver metastasis or liver cancer: = 5 × ULN Renal function:Creatinine = 1.5 × ULN Coagulation function:Activated partial thromboplastin time (APTT) = 1.5 × ULN ;International normalized ratio (INR) = 1.5 × ULN 8. Eligible fertile patients (male and female) must agree to use reliable contraceptive methods (hormonal or barrier method or abstinence, etc.) with their partners during the trial and at least 90 days after the last medication; women of childbearing age (as defined in Appendix 8) must have a negative blood or urine pregnancy test within 7 days before the first use of the study drug; 9. The subjects should be informed of the study before the trial and sign the written informed consent voluntarily. Exclusion Criteria: - When a patient has one of the following conditions, he or she will not be eligible to be recruited to the clinical study. 1. Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy, traditional chinese medicine with anti-tumor indications and other anti-tumor treatments within 2 weeks before apheresis procedure, except for the following items: 1. Nitrosourea or mitomycin C treatment was within 6 weeks before apheresis; 2. Oral administration of fluorouracil and small molecule targeted drugs was one week before apheresis. 2. Received other unlisted clinical research drugs or treatments within 4 weeks before ; 3. Major organ surgery (excluding puncture biopsy) or significant trauma occurred within 4 weeks before apheresis, or a surgery was scheduled during the trial period; 4. Received systemic corticosteroids (prednisone > 10mg/day or equivalent dose of the similar drugs) or other immunosuppressants within 14 days before apheresis; Except for the following: topical, ocular, intra articular, nasal and inhaled glucocorticoids; short-term use of glucocorticoids for preventive treatment (e.g., prevention of contrast media allergy); 5. Received immunomodulatory drugs, including but not limited to thymosin, interleukin-2, interferon, etc. within 14 days apheresis; 6. Received live attenuated vaccine within 4 weeks before apheresis; 7. The adverse reactions from previous anti-tumor therapy have not yet restored to CTCAE 5.0 grade evaluation of =1 (except for the toxicity without safety risk as judged by researchers such as alopecia). 8. Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that the central nervous system metastasis or meningeal metastasis has not been controlled, as judged by researcher inappropriate to be recruited to the study; 9. Patients with active infection within one week before apheresis and a systemic anti-infection treatment is essential at this time; 10. History of immunodeficiency, including positive HIV antibody test; 11. Hepatitis B (HBsAg positive and/or a positive hepatitis C antibody and/or a positive treponema pallidum antibody; 12. Patients with progressive interstitial pneumonitis; 13. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: 1. There are serious cardiac arrhythmia or conduction abnormalities, such as 2-3 degree ventricular arrhythmia, , atrioventricular block, and so on. 2. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months before the first administration. 3. New York Heart Association (NYHA) defined cardiac function grade = II or left ventricular ejection fraction (LVEF) of less than 50%, or as judged by other researchers to have a high risk of structural heart disease; 4. Clinically uncontrollable hypertension. 14. Patients with active or previous autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.) with active or previous autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), excluding patients with clinically stable autoimmune thyroid disease and well controlled type I diabetes mellitus; 15. Received immunotherapy and had Irae of grade 3 or above; 16. The serous cavity exudation which could not be controlled clinically was not suitable for the study; 17. Known alcohol or drug dependence; 18. Mental disorder or poor compliance; 19. Pregnant or lactating women; 20. The researchers considered that the subjects were not suitable for the clinical study because of other serious systemic diseases or other reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Super circulating tumor infiltrating lymphocytes(ScTIL)
Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with "enhanced receptor" and "superamplification factor". The obtained ScTIL is used for one-time intravenous infusion.

Locations

Country Name City State
China Shanghai East Hospital Shanghai Shanghai
China Shanghai Zhongshan Hospital Affiliated to Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai East Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The safety of ScTIL210 To assess if the ScTIL210 product will be safe to the subjects, as assessed by the incidence of treatment-related adverse events, in the treatment of malignant solid tumors. 24 weeks post infusion
Secondary The in vivo dynamic variation of reinfused ScTIL210 To assess the percentage of PD1 positive cell in total lymphocytes of peripheral blood along a series of time points after reinfusion of ScTIL210 as measured by flow cytometry. 24 weeks post infusion
Secondary The efficacy of ScTIL210 in the treatment of malignant solid tumors To assess the clinical efficacy of ScTIL210 in the treatment of malignant solid tumors, as assessed by duration of response(DOR), i.e., time from complete remission (CR) or partial remission (PR) to disease progression (PD), or to death, or to last tumor evaluation. 24 weeks post infusion
See also
  Status Clinical Trial Phase
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Completed NCT01648764 - A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05141474 - Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors Early Phase 1
Active, not recruiting NCT02999750 - EXtendedAnalysis for Cancer Treatment N/A
Completed NCT01457118 - An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Phase 2
Active, not recruiting NCT05539157 - Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors Phase 1
Recruiting NCT05468359 - Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Phase 1/Phase 2
Recruiting NCT04168528 - Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT Phase 1/Phase 2
Recruiting NCT04145622 - Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT06057038 - A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors Phase 1
Completed NCT02844400 - Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT00452413 - A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer Phase 1/Phase 2
Completed NCT03553108 - A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. Phase 1
Recruiting NCT06391775 - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy Phase 1/Phase 2
Recruiting NCT04076137 - Targeted T-cell Therapy in Solid Tumors Early Phase 1
Terminated NCT03192345 - A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02754141 - An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab Phase 1/Phase 2